Principal Financial Group Inc. Buys 11,784 Shares of Neurocrine Biosciences, Inc. $NBIX

Posted by Francis Steltz on Jul 20th, 2026

Principal Financial Group Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.2% in the first quarter, HoldingsChannel.com reports. The firm owned 238,161 shares of the company’s stock after purchasing an additional 11,784 shares during the quarter. Principal Financial Group Inc.’s holdings in Neurocrine Biosciences were worth $31,375,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at $25,000. DJE Kapital AG bought a new position in Neurocrine Biosciences during the fourth quarter worth $28,000. Geneos Wealth Management Inc. raised its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after buying an additional 202 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Neurocrine Biosciences in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

NBIX opened at $170.88 on Monday. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $181.18. The company has a market cap of $17.18 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 0.68 and a beta of 0.39. The company has a fifty day moving average price of $163.74 and a two-hundred day moving average price of $143.79.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the transaction, the director directly owned 15,860 shares of the company’s stock, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the transaction, the insider owned 54,729 shares in the company, valued at approximately $9,829,328.40. The trade was a 15.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 394,172 shares of company stock worth $62,221,181 over the last 90 days. 4.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Sanford C. Bernstein started coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They set an “outperform” rating and a $221.00 price target on the stock. BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $144.00 to $170.00 and gave the company a “market perform” rating in a research note on Monday, July 13th. Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Weiss Ratings cut Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, July 10th. Finally, Wells Fargo & Company lifted their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $192.86.

View Our Latest Research Report on Neurocrine Biosciences

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.